166 related articles for article (PubMed ID: 15894927)
1. Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer.
Singh M; Capocelli KE; Marks JL; Schleicher RB; Finlayson CA; Seligman PA
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):147-56. PubMed ID: 15894927
[TBL] [Abstract][Full Text] [Related]
2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
4. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
[TBL] [Abstract][Full Text] [Related]
5. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE
J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586
[TBL] [Abstract][Full Text] [Related]
6. Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
Chatterjee D; Bal A; Das A; Singh G
Virchows Arch; 2015 Sep; 467(3):303-10. PubMed ID: 26063415
[TBL] [Abstract][Full Text] [Related]
7. Pathological predictive factors for tumor response in locally advanced breast carcinomas treated with anthracyclin-based neoadjuvant chemotherapy.
Patel T; Gupta A; Shah M
J Cancer Res Ther; 2013; 9(2):245-9. PubMed ID: 23771367
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant induction chemotherapy.
Schwartz G
Minerva Ginecol; 2005 Jun; 57(3):327-48. PubMed ID: 16166939
[TBL] [Abstract][Full Text] [Related]
9. Summated chemotherapy dose-intensity versus loco-regional response in locally advanced breast cancer: its possible implications.
Datta NR; Rajkumar A; Basu R
Indian J Cancer; 2003; 40(4):127-34. PubMed ID: 14716108
[TBL] [Abstract][Full Text] [Related]
10. Axillary reverse mapping: Is it feasible in locally advanced breast cancer patients?
Khandelwal R; Poovamma CU; Shilpy C; Prema M; Anthony P
Breast Dis; 2014 Jan; 34(4):151-5. PubMed ID: 24934169
[TBL] [Abstract][Full Text] [Related]
11. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
[TBL] [Abstract][Full Text] [Related]
12. Decreasing expression of HIF-1α, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer.
Zhao K; Hu M; Yang R; Liu J; Zeng P; Zhao T
Medicine (Baltimore); 2023 May; 102(20):e33820. PubMed ID: 37335690
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study of safe breast conservation in large and locally advanced cancers with use of radiopaque markers to mark pre-neoadjuvant chemotherapy tumor margins.
Aggarwal V; Agarwal G; Lal P; Krishnani N; Mishra A; Verma AK; Mishra SK
World J Surg; 2008 Dec; 32(12):2562-9. PubMed ID: 18030518
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
16. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
[TBL] [Abstract][Full Text] [Related]
17. Alteration in steroid hormone and Her-2/neu receptor status following neoadjuvant chemotherapy in locally advanced breast cancer: Experience at a tertiary care centre in India.
Ramteke P; Seenu V; Prashad R; Gupta SD; Iyer V; Deo S; Gogia A; Mathur S
Indian J Cancer; 2016; 53(3):366-371. PubMed ID: 28244460
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
19. A Comparative Validation of Primary Surgical Versus Post-neo-adjuvant Chemotherapy Sentinel Lymph Node Biopsy for Stage III Breast Cancers.
Agarwal G; Rajan S; Gambhir S; Lal P; Krishnani N; Kheruka S
World J Surg; 2016 Jul; 40(7):1583-9. PubMed ID: 26324160
[TBL] [Abstract][Full Text] [Related]
20. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
